Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5812)	3/7/2002 9:40:13 AM
From: Crossy	Respond to of 52153

To Biomaven Peter, many thx for your reply. I thought that Soltara must be quite important for SEPR's future otherwise the 50% plummeting would not have happened. I will watch SEPR from the sidelines (it will surely drop further and will be quite vulnerable for the next 2 weeks I guess) and will try to bottom fish it.. thx alot CROSSY BTW: In the past biospace.com provided nice info on trials/pipelines free of charge. Now they want $2500 per year for the same data, mostly destilled out of press releases. Are there any alternatives to look at which aren't that pricey but have a similar amount of trial coverage ??